Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease

doi:10.4254/wjh.v16.i5.832

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2361)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

HTML

1045

Figures (1-5)

178

Tables (1-1)

150

Sum=1438

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

170

Download

432

Sum=602

Publishing Process of This Article

Item

Count

Browse

Download

194

Sum=247

May 27, 2024 (publication date) through Jan 7, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. May 27, 2024; 16(5): 832-842
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.832

Full Size Figure Download Figure

Figure 1 Alpha diversity analysis according to different metrics. A: Observed; B: ACE; C: Shannon. Statistical confidence was accessed using the multivariate Kruskal-Wallis test. ^aP-value < 0.05. MASLD: Metabolic-dysfunction associated steatotic liver disease; LOLA: Ornithine aspartate.

Citation: Lange EC, Rampelotto PH, Longo L, de Freitas LBR, Uribe-Cruz C, Alvares-da-Silva MR. Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease. World J Hepatol 2024; 16(5): 832-842
URL: https://www.wjgnet.com/1948-5182/full/v16/i5/832.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i5.832